Cyclobenzaprine, a muscle relaxant commonly prescribed for short-term relief of muscle spasms, does not typically trigger a positive result on standard drug screenings. These screenings primarily target substances such as opioids, amphetamines, benzodiazepines, cocaine, and marijuana. While uncommon, specific circumstances or specialized tests could potentially detect its presence.
Understanding how different substances are metabolized and screened for is essential for both patients and employers. Knowing that common drug tests do not usually include cyclobenzaprine provides reassurance to individuals taking the medication under medical supervision. Historically, drug testing has evolved to focus on commonly abused substances, with panels being updated as trends in drug use change. The absence of cyclobenzaprine on standard panels reflects its generally low potential for abuse and the focus on other higher-risk drugs.
